Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

NCT05797831 is registered in ClinicalTrials.gov with Kartos Therapeutics, Inc. as lead sponsor.

NCT NCT05797831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05797831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Lead sponsor
Kartos Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 17, 2023
Completion date
July 31, 2027
Enrollment
268 (estimated)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer